Systemic Treatment of Thyroid Cancer: ASCO Guideline.

It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment.

它旨在供临床医生自愿使用，并应与独立的专业判断一起使用。

Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases.

该指导可能不适用于所有患者、干预措施、疾病或疾病阶段。

Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care.

该指导基于相关文献的回顾和分析，并不旨在作为照护标准的声明。

ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information.

美国临床肿瘤学会（ASCO）不支持第三方药物、设备、服务或疗法，并不对由此信息使用引起的任何伤害承担责任。

See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more.

更多完整免责声明，请参见附录1和仅在线的附录2。

Background

To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers.

为不同类型甲状腺癌的系统治疗使用提供基于证据的推荐意见。

Methods

The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations.

美国临床肿瘤学会召集了一个多学科专家小组，以评估证据并制定推荐意见。

The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies.

文献检索包括2000年1月1日至2025年11月5日之间发表的研究，涵盖系统评价、荟萃分析、随机对照试验和观察性研究。

Outcomes of interest included overall survival, disease-free survival, and safety.

关注的结果包括总生存、无病生存和安全性。

Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.

专家小组成员利用现有证据和非正式共识来制定基于证据的指南建议。

Results

A total of 66 publications were identified to inform the evidence base for this guideline.

共有66篇出版物被确定为本指南的证据基础。

recommendations

Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer.

基于证据的推荐意见涉及在分化良好、分化高分级或分化不良、未分化（间变性）和髓样甲状腺癌患者中使用系统性治疗。更多信息可在https://ascopubs.org/topics/asco-guidelines/head-neck-cancer中找到。